Clinical Trial Participant Discusses Approval of New Myeloma Treatment From a Patient Perspective

The second monoclonal antibody for myeloma, elotuzumab (Empliciti) was approved today by the U.S. Food and Drug Administration for use in combination with two other therapies to treat people with mult... Author: P2Professional Added: 12/03/2015
Source: Oncology Tube - Category: Cancer & Oncology Source Type: podcasts